A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone

Wenzel, Kevin; Thomas, Julia; Carrano, Jennifer; Stidham, Jennifer; Fishman, Marc

doi:10.1016/j.josat.2024.209366

Journal of Substance Use and Addiction Treatment

2024

DOI: 10.1016/j.josat.2024.209366

|View full text |Cite

A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone

Kevin Wenzel,

Julia Thomas,

Jennifer Carrano

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Correlates of post-hospitalization naltrexone adherence for alcohol use disorder

Y.Bernstein,

Magane,

Dukes

et al. 2024

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Correlates of post-hospitalization naltrexone adherence for alcohol use disorder

Y.Bernstein,

Magane,

Dukes

et al. 2024

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Follow-up and reasons for extended-release naltrexone discontinuation for alcohol use disorder after hospital initiation

Martin,

Seraydarian,

Gasper

et al. 2024

BMJ Open Qual

View full text Add to dashboard Cite

Only 1.9% of the individuals in the USA with alcohol use disorder (AUD) receive medication for AUD. Hospitalisation presents an opportunity to identify patients with AUD and offer treatment. Extended-release naltrexone (XR-NTX) is a Food and Drug Administration-approved medication for AUD that reduces drinking days and heavy drinking days. XR-NTX can reduce healthcare costs, decrease acute care utilisation and increase retention in treatment. We offered and initiated XR-NTX during hospitalisation to patients with moderate-to-severe AUD. We describe the follow-up rates for XR-NTX after hospital initiation and the reasons for XR-NTX discontinuation in the outpatient setting after hospital initiation. We performed a retrospective chart review of 62 hospitalised patients with moderate-to-severe AUD who received XR-NTX between 1 November 2019 and 31 December 2020. Twenty-two patients (35.5%) received ≥1 dose of XR-NTX within the first 3 months of discharge, 22 (35.5%) stopped XR-NTX and 18 (29.0%) did not follow-up. Overall, 44 (71.0%) patients followed up after discharge. Among those that discontinued XR-NTX, the most common reasons were: (1) a preference for oral NTX; (2) clinicians switching patients to oral NTX after patients missed an XR-NTX dose; (3) clinician challenges in prescribing XR-NTX; and (4) patient obstacles to accessing outpatient care. Our study highlights several opportunities to address modifiable reasons to improve access to and retention in XR-NTX treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone

Cited by 2 publications

References 24 publications

Correlates of post-hospitalization naltrexone adherence for alcohol use disorder

Correlates of post-hospitalization naltrexone adherence for alcohol use disorder

Follow-up and reasons for extended-release naltrexone discontinuation for alcohol use disorder after hospital initiation

Contact Info

Product

Resources

About